Preserved bevacizumab (Avastin®) eye drops for application in multidose containers – an in-vitro characterisation
Equivalence tests demonstrated that bevacizumab is stable after dilution, storage and preservation with BAC. Our study shows that preserved bevacizumab applied in mutidose containers can be considered as a cost-effective alternative to the otherwise single-dose treatments.
Authors
- Tania Brandstoetter (ORCID: https://orcid.org/0000-0003-4037-5352)
- Georg Mlynek (ORCID: https://orcid.org/0000-0003-1454-4044)
- Andrea Hoelbl‐Kovacic (ORCID: https://orcid.org/0000-0001-6219-8794)
- Lukas Wimmer (ORCID: https://orcid.org/0000-0002-7691-6838)
- Alexander Tichy (ORCID: https://orcid.org/0000-0001-8668-3858)
- Barbara Nell
- Klara R. Klein (ORCID: https://orcid.org/0000-0002-5894-9054)
- Ulrike Lessiak
- Lisa Scheiblecker
Institutions
- University of Vienna (AT)
- University of Veterinary Medicine Vienna (AT)
- BOKU University (AT)
Publication Details
- Journal
- BMC Veterinary Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1186/s12917-025-04592-4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00